David Turkaly, an analyst from JMP Securities, reiterated the Buy rating on TELA Bio (TELA – Research Report). The associated price ...

TELA Bio, Inc. (NASDAQ: TELA) has announced impressive financial results for the third quarter of 2024, achieving a record ...

The company said, “Reiterated full year 2024 revenue guidance of $74.5 million to $76.5 million, representing 27% to 31% year-over-year ...

Third Quarter 2024 Results Key Financial Results Revenue: US$19.0m (up 26% from 3Q 2023).

The skies will be mostly cloudy. The high will reach 87° on this humid day. Good air quality (0-50) Primary pollutant O₃ 58 μg/m³ Pressure is the weight of the air in the atmosphere. It is normalized ...

TELA Bio Inc (NASDAQ:TELA) reported a strong third quarter with a 26% year-over-year revenue increase, reaching $19 million. The company experienced significant growth in its European business ...

TELA has been the subject of a number of research reports. Lake Street Capital reduced their target price on shares of TELA Bio from $14.00 to $8.00 and set a “buy” rating for the company in a ...

Everard Best met Téla D’Amore on the streets of New York City’s Lower East Side . Years later, the duo would helm a defining ...

MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction ...

Full Year Revenue Guidance: $74.5 million to $76.5 million for 2024, reflecting growth of 28% to 31% over 2023. TELA Bio Inc ...

MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction ...